Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E12.96 EPS (ttm)2.74 Insider Own0.04% Shs Outstand5.55B Perf Week-5.44%
Market Cap196.92B Forward P/E11.49 EPS next Y3.09 Insider Trans-7.61% Shs Float5.55B Perf Month-7.56%
Income15.47B PEG- EPS next Q0.67 Inst Own73.10% Short Float0.95% Perf Quarter1.66%
Sales50.66B P/S3.89 EPS this Y62.30% Inst Trans-0.40% Short Ratio1.72 Perf Half Y-8.21%
Book/sh11.72 P/B3.03 EPS next Y7.26% ROA9.60% Target Price41.36 Perf Year-14.60%
Cash/sh1.86 P/C19.03 EPS next 5Y0.00% ROE25.00% 52W Range27.88 - 44.56 Perf YTD-9.49%
Dividend1.52 P/FCF52.64 EPS past 5Y14.70% ROI14.70% 52W High-20.42% Beta0.70
Dividend %4.29% Quick Ratio0.80 Sales past 5Y0.90% Gross Margin80.40% 52W Low27.19% ATR1.02
Employees88300 Current Ratio1.00 Sales Q/Q-8.30% Oper. Margin32.10% RSI (14)41.39 Volatility1.84% 2.00%
OptionableYes Debt/Eq0.80 EPS Q/Q-10.30% Profit Margin31.20% Rel Volume2.38 Prev Close38.19
ShortableYes LT Debt/Eq0.56 EarningsApr 28 BMO Payout51.30% Avg Volume30.54M Price35.46
Recom2.50 SMA20-5.95% SMA50-0.44% SMA200-3.08% Volume72,680,605 Change-7.15%
Feb-27-20Upgrade Standpoint Research Hold → Buy
Feb-27-20Initiated Barclays Equal Weight $36
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Outperform $46
Oct-17-19Resumed BofA/Merrill Neutral $37
Jul-30-19Downgrade Morgan Stanley Overweight → Equal-Weight $48 → $40
Jul-30-19Downgrade BofA/Merrill Buy → Neutral
Jun-04-19Resumed Morgan Stanley Overweight $48
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Jun-01-20 05:39PM  
05:18PM  
05:15PM  
04:37PM  
04:22PM  
04:09PM  
04:00PM  
03:18PM  
02:50PM  
02:25PM  
02:22PM  
01:29PM  
01:15PM  
01:08PM  
12:31PM  
12:17PM  
11:52AM  
11:42AM  
11:27AM  
11:26AM  
10:55AM  
10:30AM  
10:01AM  
10:00AM  
09:52AM  
09:00AM  
08:57AM  
08:37AM  
08:32AM  
07:47AM  
07:03AM  
06:32AM  
06:02AM  
02:16AM  
May-31-20 05:32PM  
10:19AM  
May-30-20 07:03AM  
May-29-20 05:49PM  
04:55PM  
04:46PM  
04:15PM  
11:43AM  
09:59AM  
08:37AM  
08:00AM  
07:48AM  
06:43AM  
02:30AM  
May-28-20 02:56PM  
01:56PM  
11:34AM  
11:31AM  
11:30AM  
10:56AM  
09:53AM  
08:30AM  
12:00AM  
May-27-20 11:39AM  
09:05AM  
03:49AM  
May-26-20 02:03PM  
01:47PM  
11:53AM  
10:54AM  
10:52AM  
10:13AM  
09:59AM  
09:39AM  
07:30AM  
May-24-20 08:21AM  
07:33AM  
May-23-20 09:15AM  
May-22-20 04:30PM  
04:26PM  
11:50AM  
09:22AM  
07:46AM  
07:29AM  
06:16AM  
05:37AM  
02:51AM  
May-21-20 03:48PM  
10:46AM  
04:22AM  
May-20-20 04:50PM  
04:30PM  
12:00PM  
11:52AM  
08:11AM  
06:42AM  
May-19-20 03:18PM  
02:59PM  
11:39AM  
11:39AM  
08:11AM  
06:04AM  
05:52AM  
May-18-20 09:24PM  
02:54PM  
02:47PM  
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dolsten MikaelPresident R&DMay 18Sale37.7895,3533,602,681174,918May 19 05:37 PM
DAMICO JENNIFER B.SVP & ControllerApr 29Sale38.352,18183,6419,647May 01 03:56 PM
JOHNSON RADY AExecutive Vice PresidentApr 29Sale38.3613,125503,47563,940May 01 03:56 PM
ROGERS DAWNExecutive Vice PresidentApr 29Sale38.1313,000495,6904,823May 01 03:56 PM
LANKLER DOUGLAS MExecutive Vice PresidentApr 29Sale37.8565,0002,460,37278,276May 01 03:56 PM
PFIZER INC10% OwnerMar 16Buy16.00312,5005,000,0001,481,719Mar 16 07:15 PM
GOETTLER MICHAELGroup PresidentFeb 28Option Exercise27.3722,852625,45953,036Mar 03 12:54 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3715,996437,81187,956Mar 03 12:54 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3738,8481,063,270172,542Mar 03 12:54 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 28Option Exercise27.3737,9341,038,254140,256Mar 03 12:54 PM
ROGERS DAWNExecutive Vice PresidentFeb 28Option Exercise27.3717,824487,84330,045Mar 03 12:54 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.3791,4082,501,837222,496Mar 03 12:55 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37100,5482,751,999504,427Mar 03 12:55 PM
BOURLA ALBERTChairman & CEOFeb 28Option Exercise27.3733,135906,905232,888Mar 03 12:49 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3727,422750,540140,744Mar 03 12:49 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37173,6754,753,485556,084Mar 03 12:49 PM
YOUNG JOHN DGroup PresidentFeb 26Option Exercise34.59144,9285,013,060503,738Feb 28 07:32 PM
ROGERS DAWNExecutive Vice PresidentFeb 26Option Exercise34.5915,097522,20524,995Feb 28 07:28 PM
SUSMAN SALLYExecutive Vice PresidentFeb 26Option Exercise34.5972,4642,506,530180,558Feb 28 07:28 PM
JOHNSON RADY AExecutive Vice PresidentFeb 26Option Exercise34.5933,4141,155,79093,211Feb 28 07:24 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 26Option Exercise34.5988,5673,063,533189,936Feb 28 07:25 PM
GOETTLER MICHAELGroup PresidentFeb 26Option Exercise34.5920,129696,26245,557Feb 28 07:22 PM
Hwang AngelaGroup PresidentFeb 26Option Exercise34.5914,493501,31332,470Feb 28 07:22 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 26Option Exercise34.59144,9285,013,060482,320Feb 28 07:19 PM
BOURLA ALBERTChairman & CEOFeb 26Option Exercise34.5988,5673,063,533274,479Feb 28 07:16 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 26Option Exercise34.5924,155835,521131,196Feb 28 07:15 PM
Gottlieb ScottDirectorJan 30Buy37.001,00036,9974,000Jan 31 08:06 AM
PFIZER INC10% OwnerSep 17Buy18.0050,000900,0004,593,847Sep 19 04:19 PM
Gottlieb ScottDirectorAug 23Buy34.723,000104,1603,000Aug 26 09:27 AM
DAMELIO FRANK AExecutive Vice PresidentJul 02Sale44.09153,1846,753,385337,392Jul 03 04:06 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentJun 20Sale44.0030,0001,320,00080,094Jun 21 04:08 PM